Medical Management of Obesity: Current Trends and Future Perspectives
References
- The Lancet Gastroenterology Hepatology. Obesity: another ongoing pandemic, Lancet Gastroenterol Hepatol. 2021 Jun;6(6):411. doi: 10.1016/S2468-1253(21)00143-6
- Bae JP, Nelson DR, Boye KS, Mather KJ. Prevalence of complications and co-morbidities in males and females with obesity: Real-world insights from claims data analysis. Diabetes Obes Metab. 2024 Nov;26(11):5005-5012. doi: 10.1111/dom.15914
- de Ceglia M, Decara J, Gaetani S, Rodriguez de Fonseca F. Obesity as a Condition Determined by Food Addiction: Should Brain Endocannabinoid System Alterations Be the Cause and Its Modulation the Solution? Pharmaceuticals (Basel). 2021 Sep 29;14(10):1002. doi: 10.3390/ph14101002
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. doi: 10.1152/physrev.00034.2006
- Guccio N, Gribble FM, Reimann F. Glucose-Dependent Insulinotropic Polypeptide-A Postprandial Hormone with Unharnessed Metabolic Potential. Annu Rev Nutr. 2022 Aug 22;42:21-44. doi: 10.1146/annurev-nutr-062320-113625
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892
- Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024 Apr 6;403(10434):e21-e31. doi: 10.1016/S0140-6736(24)00351-9
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038
- Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816
- Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Ann Intern Med. 2020 Aug 18;173(4):278-286. doi: 10.7326/M20-0864
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6
- Karagiannis T, Malandris K, Avgerinos I, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024 Jul;67(7):1206-1222. doi: 10.1007/s00125-024-06144-1
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389:2221-2232. doi: 10.1056/NEJMoa2307563
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-322. doi: 10.1056/NEJMoa1603827
- Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2410027
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. New Engl J Med. 2024 Jul 25;391(4):299-310. doi: 10.1056/NEJMoa2401943
- Skelley JW, Swearengin K, York AL, Glover LH. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc (2003). 2024 Jan-Feb;64(1):204-211.e4. doi: 10.1016/j.japh.2023.10.037
- Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Saf. 2024 May;47(5):439-451. doi: 10.1007/s40264-023-01392-3
- Lilly.com [Internet]. Indianapolis, IN: Eli Lilly and Company; c2025.
Zepbound.package insert; (tirzepatide) injection ; c2021 [cited 2025 Jan 2]. Available from:https://zepbound.lilly.com/ - Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. 2024 Apr 24;14(4):
e083550 . doi: 10.1136/bmjopen-2023-083550 - Drummond RF, Seif KE, Reece EA. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. Am J Obstet Gynecol. 2025 Jan;232(1):17-25. doi: 10.1016/j.ajog.2024.08.024
- Obesity in Pregnancy: ACOG Practice Bulletin, Number 230. Obstet Gynecol. 2021 Jun 1;137(6):e128-e144. doi: 10.1097/AOG.0000000000004395
- Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab. 2017 Mar;19(3):336-347. doi: 10.1111/dom.12824
- Monami M, Nreu B, Scatena A, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obstet Metab. 2017 Sep;19(9):1233-1241. doi: 10.1111/dom.12926
- Alenzi KA, Alsuhaibani D, Batarfi B, Alshammari TM. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2024 May 27;15:
1364110 . doi: 10.3389/fphar.2024.1364110 - He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022 May 1;182(5):513-519. doi: 10.1001/jamainternmed.2022.0338
- Joo JH, Sharma N, Shaia J, et al. The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Retinopathy at a Tertiary Care Center. Ophthalmol Sci. 2024 May 6;4(6):
100547 . doi: 10.1016/j.xops.2024.100547 - Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity Management in Adults: A Review. JAMA. 2023 Nov 28;330(20):2000-2015. doi: 10.1001/jama.2023.19897
- Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guidelinek. J Clin Endocrinol Metab. 2015 Feb;100(2):342-362. doi: 10.1210/jc.2014-3415
- ObesityMedicine [Internet]. Centennial, CO: Obesity Medicine Association; c2025. Tondt J, Freshwater M, Benson-Davies S, et al.
Obesity Algorithm eBook ; 2024 [cited 2025 Jan 2]. Available from:https://obesitymedicine.org/resources/obesity-algorithm/ - Greenway FL, Aronne LJ, Raben A. et al. Erratum: A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. Obesity. 2018 Nov;27(suppl 1A):1210. doi: 10.1002/oby.22347
- Busebee B, Ghusn B, Cifuentes L, Acosta A. Obesity: A Review of Pathophysiology and Classification. Mayo Clin.Proc. 2023 Dec;98(12):1842-1857. doi: 10.1016/j.mayocp.2023.05.026
- Li H, Xu Y, Jiang Y, et al. The melanocortin action is biased toward protection from weight loss in mice. Nat Commun. 2023 Apr 17;14(1):2200. doi: 10.1038/s41467-023-37912-z
- Mountjoy KG. Pro-Opiomelanocortin (POMC) Neurones, POMC-Derived Peptides, Melanocortin Receptors and Obesity: How Understanding of this System has Changed Over the Last Decade. J Neuroendocrinol. 2015 Jun;27(6):406-18. doi: 10.1111/jne.12285
- Roth CL, Scimia C, Shoemaker AH, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024 Jun;12(6):380-389. doi: 10.1016/S2213-8587(24)00087-1
- TrialScreen [Internet]. Boston, MA: TrialScreen; c2021-2025.
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients 2023 Aug 7 [cited 2025 Jan 14]. Available from:https://app.trialscreen.org/trials/phase-1-2-1b-2a-to-evaluate-safety-efficacy-setmelanotide-obese-patients-trial-nct02041195 - ClinicalTrials [Internet]. Bethesda, MD: National Library of Medicine; c2025.
Effects of RM-493 on Energy Expenditure in Obese Individuals (NCT01867437) ; 2017 Apr 20 [cited 2025 Jan 14]. Available from:https://clinicaltrials.gov/study/NCT01867437 - ClinicalTrials [Internet]. Bethesda, MD: National Library of Medicine; c2025.
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers (NCT02431442) ; 2015 May 1 [cited 2025 Jan 14]. Available from:https://clinicaltrials.gov/study/NCT02431442 - Al-Massadi O, Ferno J, Dieguez C, Nogueiras R, Quinones M. Glucagon Control on Food Intake and Energy Balance. Int J Mol Sci. 2019 Aug 11;20(16):3905. doi: 10.3390/ijms20163905
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972
- Kee TR, Khan SA, Neidhart MB, et al. The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases. Exp Mol Med. 2024 Feb;56(1):129-141. doi: 10.1038/s12276-023-01144-4
- Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023 Sep 7;389(10):877-888. doi: 10.1056/NEJMoa2302392
- Boyle CN, Zheng Y, Lutz TA. Mediators of Amylin Action in Metabolic Control. J Clin Med. 2022 Apr 15;11(8):2207. doi: 10.3390/jcm11082207
- Pullman J, Darsow T, Frias JP. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manag. 2006;2(3):203-12. doi: 10.2147/vhrm.2006.2.3.203
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021 Dec 11;398(10317):2160-2172. doi: 10.1016/S0140-6736(21)01751-7
- Swan J, Szabo Z, Peters J, et al. Inhibition of activin receptor 2 signalling ameliorates metabolic dysfunction-associated steatotic liver disease in western diet/L-NAME induced cardiometabolic disease. Biomed.Pharmacother. 2024 Jun;175:
116683 . doi: 10.1016/j.biopha.2024.116683 - Garito T, Roubenoff R, Hompesch M, et al. Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. Diabetes Obes Metab. 2018 Jan;20(1):94-102. doi: 10.1111/dom.13042
- Heymsfield SB, Coleman LA, Miller R, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):
e2033457 . doi: 10.1001/jamanetworkopen.2020.33457
DOI: https://doi.org/10.14797/mdcvj.1503 | Journal eISSN: 1947-6108
Language: English
Page range: 62 - 73
Submitted on: Oct 22, 2024
Accepted on: Dec 30, 2024
Published on: Feb 18, 2025
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2025 Andres Calderon Valladares, Maria Aguilera Astudillo, Alexsandra Rojas Drinnon, Abhishek Kansara, Samaneh Dowlatshahi, Jawairia Shakil, Bhargavi Patham, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.